26 Feb 2010
FDA Press Release - FDA Approves Therapy to Treat Gaucher Disease
New drug will offer a treatment alternative for patients with rare genetic disorder
SILVER SPRING, Md., Feb. 26 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration has approved velaglucerase alfa for injection (VPRIV) to treat children and adults with a form of the rare genetic disorder Gaucher disease.
SOURCE U.S. Food and Drug Administration